The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,374.00
Bid: 12,374.00
Ask: 12,376.00
Change: 256.00 (2.11%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,376.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

Mon, 19th Feb 2024 16:51

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

The FTSE 100 index closed up 16.79 points, 0.2%, at 7,728.50. The FTSE 250 ended up 24.97 points, 0.1%, at 19,216.90, and the AIM All-Share closed up 2.45 points, 0.3%, at 756.33.

The Cboe UK 100 ended up 0.3% at 773.62, the Cboe UK 250 closed up 0.2% at 16,639.38, and the Cboe Small Companies ended up 0.2% at 14,519.37.

In European equities on Monday, the CAC 40 in Paris ended flat, while the DAX 40 in Frankfurt ended down 0.2%.

Overnight, the People's Bank of China will announce its interest rate decision, with FXStreet-cited consensus expecting the key one-year loan prime rate, which serves as a benchmark for corporate loans, to remain at 3.45%. On Sunday, the PBoC kept the one-year medium-term lending facility rate steady at 2.50%.

"Investors will also monitor developments surrounding additional stimulus measures from Chinese authorities in the coming months," said analysts at XS.com.

Sentiment in China was upbeat on Monday, after the Lunar New Year holiday period.

China's new year holiday spending last week surged past pre-pandemic levels, official figures showed, a rare bright spot for an economy struggling with sluggish consumption and deflation. Domestic spending on entertainment, dining and travel soared during this year's "Golden Week", which officially ended on Saturday, according to a statement from Beijing's Ministry of Culture & Tourism.

The pound was quoted at USD1.2589 at the London equities close Monday, higher compared to USD1.2582 at the close on Friday. The euro stood at USD1.0764 at the European equities close Monday, lower against USD1.0775 at the same time on Friday. Against the yen, the dollar was trading at JPY150.17, up compared to JPY150.13 late Friday.

In the FTSE 100, AstraZeneca rose 2.6%.

The Cambridge-based pharmaceutical announced the purchase back in January. The deal was valued at up to USD1.1 billion for Icosavax, a US-based biopharmaceutical company focused on the development of vaccines against respiratory viruses.

According to AstraZeneca, Icosavax's lead investigational vaccine candidate IVX-A12 is a "potential first-in-class" for targeting both respiratory syncytial virus and human metapneumovirus.

As a result of the acquisition, Icosavax has become a subsidiary of AstraZeneca, with operations in Seattle, US.

Earlier on Monday, AstraZeneca announced new study data and a new approval for its cancer medication Tagrisso.

NatWest lost 2.0%.

The Edinburgh-based bank said it is starting a share buyback programme of up to GBP300 million with a nominal value of around GBP1.08 per share. The programme will run until July 18 latest.

In the FTSE 250, Currys shares closed up 36% at 64.20 pence each.

Chinese e-commerce firm JD.com became the latest to throw its hat in the ring for a possible takeover of the consumer electronics retailer.

JD.com, noting press coverage, said it is mulling an acquisition of Currys. The Telegraph newspaper on Sunday reported JD.com has held early talks with Currys.

JD.com noted that there is no certainty that its interest will result in a bid.

On Sunday, Currys said it rejected a takeover tilt from US private equity firm Elliott Investment Management LP.

Currys said it received an unsolicited proposal worth around GBP702.8 million from Elliott, or 62 pence per share.

Currys said the Elliott bid "significantly undervalued the company and its future prospects".

Bank of Georgia jumped 6.6%, after it snapped up Armenia's Ameriabank.

Following last week's announcement that it was in talks with Ameriabank regarding a potential acquisition, Bank of Georgia confirmed the signing of a conditional agreement to acquire the leading Armenian bank for USD303.6 million.

Bank of Georgia said that the Yerevan-based bank has "an attractive franchise, in an attractive market, with similar characteristics to Georgia".

On London's AIM, SpaceandPeople shares surged 49%.

For the year ended December 31, the provider of retail space expects revenue to be slightly above market expectations. Thanks to a solid performance in the second half, SpaceandPeople estimates that revenue for the full year was around GBP5.8 million, up 23% from GBP4.7 million in 2022.

Brent oil was quoted at USD83.53 a barrel at the London equities close Monday, up from USD82.88 late Friday. Gold was quoted at USD2,013.67 an ounce at the London equities close Monday, up against USD2,009.01 at the close on Friday.

In Tuesday's UK corporate calendar, there will be full year results from Antofagasta, Barclays, and InterContinental Hotels.

The economic calendar for Tuesday an interest rate decision from China overnight, as well as meeting minutes from the Reserve Bank of Australia.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.